Navigation Links
Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
Date:4/14/2011

MISSISSAUGA, Ontario, April 14, 2011 /PRNewswire/ -- Theramed Corporation ("Theramed") announces that it has obtained the exclusive distribution rights in Canada for the EBB® Complete Tamponade System and the JETTY® Vaginal Repair Balloon, two newly developed medical devices used to advance the practice of obstetrics, from Glenveigh International, LLC ("Glenveigh").  [Both] medical device products have been approved for sale by Health Canada, and Theramed will begin distributing these products immediately.

About the EBB® Complete Tamponade System

EBB® is a complete tamponade solution for the emergency of postpartum hemorrhage.  Designed by world-renowned maternal-fetal medicine specialists Michael A. Belfort and Gary A. Dildy, the EBB® balloon is made of a malleable yet extremely strong material, allowing EBB to expand and conform to any uterine shape. Ebb also features a vaginal balloon to control vaginal bleeding and act as an anchor to support the uterine balloon. External ports allow independent control of inflation, deflation, irrigation, and drainage.

About the JETTY® Vaginal Repair Balloon

JETTY® is indicated for use during episiotomy and vaginal laceration repair to temporarily prevent the postpartum discharge of fluids from the vagina in order to assist with the repair procedure.  JETTY® provides clarity and cleanliness for a timely, effective repair, and it eliminates the need for vaginal packing with gauze or sponges.

About Theramed Corporation

Theramed Corporation, headquartered in Mississauga, Ontario, is a specialty pharmaceutical company, focused on the development, acquisition, in-licensing, marketing, and distribution of medical products in Canada. The Company is dedicated to bringing new-to-market and well-established healthcare innovations to Canadian Physicians and Hospitals, be these Pharmaceuticals, Biotech products, or Medical Devices. The company currently markets Delatestryl®, Viroptic®, CollatampG® and FSME IMMUNE®.

About Glenveigh International, LLC

Glenveigh International is the subsidiary of Glenveigh Medical LLC responsible for its ex-U.S. business. Glenveigh is a life science and medical technology company focused on advancing the practice of obstetrics, with aspirations to rapidly become the market leader in the OB/GYN field. Formed in 2004 by a maternal-fetal medicine (MFM) specialist, Glenveigh is founded on the core mission of improving the lives of pregnant mothers and their babies.

http://www.theramed.com


'/>"/>
SOURCE Theramed Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
2. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
3. Core Essence Secures $11.5 Million Series B Financing
4. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
5. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
6. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
7. PLC Systems Secures $4 Million in Financing
8. Biomatrica Secures Strategic Investment from IQT
9. Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
10. TechniScan Secures $10 Million Equity Financing Facility
11. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
(Date:2/10/2016)... 10, 2016 Convergence scenarios are ... various technologies that results in diverse solutions ... opportunities create a cyclical system where technology ... the development of new technologies. ... technology convergences, which are constantly fostering new ...
Breaking Medicine Technology:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
Breaking Medicine News(10 mins):